Navigation Links
Denosumab Reduces Bone Erosion

According to results of a 227 patient Phase 2 trial presented at EULAR 2007, the Annual Treatment with denosumab 60 mg and 180 mg (with background methotrexate) reduces the progression of bone erosion .

Denosumab is a fully human monoclonal antibody which binds to and inhibits the RANK Ligand. The RANK Ligand is the essential mediator of osteoclast formation, function, and survival and thereby plays a key role in rheumatoid arthritis (RA) associated bone erosions (osteoclasts are the cells responsible for the break down of bone material).

Bone status in patients hands and feet was assessed by radiographs at initiation of trial, six and 12 months to assess the capacity of denosumab to reduce progression of RA associated bone erosion. Researchers gathered data on erosion score (a measure of damage to joints), joint space narrowing (a measure of reduced space between bones in each joint) and derived the van der Heijde modified Total Sharp Score (TSS)

Professor Desiree van der Heijde of Leiden University Medical Center and lead author of the study commented, These data show the significant potential of denosumab, revealing that patients receiving denosumab experienced a reduced progression of erosions compared to control. Most significant was the difference observed between the control group and the group receiving denosumab 180mg. The reduction in progression of erosions was already present in this group as early as 6 months.

In the double-blind, placebo-controlled, phase 2 study, 227 patients were randomly assigned to receive subcutaneous denosumab injections or placebo at initiation of trial, and after six months, to determine if denosumab could reduce the progression of bone erosions in patients with RA on background methotrexate (MTX standard RA treatment).

Mean erosion scores were significantly reduced for the groups treated with denosumab compared to the control group. Change in mean erosion score at 12 months was reported as 0.33 and 0.19 for treatment with denosumab 60 mg and 180 mg respectively, compared with the change in score for the control group of 1.34 (respective p= 0.01 and p= 0.007).

For the 180mg group the reduction in progression in erosions was already significantly less as compared to the control group after 6 months (0.05 vs. 0.59, p-value = 0.02) and a trend was seen in the 60 mg group (0.25).

An increase in TSS was observed in the control group of patients at 12 months, significantly higher than that observed in patients in the treatment groups. For patients receiving denosumab, the progression in TSS at 12 months was 0.85 and 0.97 for denosumab 60mg and 180mg respectively as compared to 1.87 for the control group (respectively, p=0.03 and p=0.18).

No specific differences in the in Joint Space Narrowing (JSN) were detected between the denosumab and the control groups.In this study, safety was continually monitored and an adverse event profile similar to that of patients receiving placebo was observed in patients receiving treatment with denosumab.


'"/>




Related medicine news :

1. Drug Reduces Risk of Clogged Arteries, Veins
2. Sunshine Reduces MS Risk
3. Estrogen in Food Reduces Cancer Risk
4. Dental Procedure Reduces Preterm Births
5. Vaccine Reduces antibiotic-resistant infections in Children
6. Eating Fiber Reduces The Risk Of Heart Disease
7. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
8. Anti-tobacco Advertising Can Reduces smoking Among Teens
9. Eating Fish Reduces Heart Disease
10. Co-trimoxazole Use Reduces Childhood AIDS –Related Death
11. NSAIDS, Reduces The Risk Of Oral Cancer But Causes Heart Attacks
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/16/2017)... ... January 16, 2017 , ... ... Aesthetic Surgery Journal , the official journal of The American Society for Aesthetic ... retraction surgery. The procedure is designed to correct drooping, retracted lower eyelids, which ...
(Date:1/16/2017)... ... 16, 2017 , ... San Francisco dentist, Dr. Ben Amini , the ... device which is capable of taking digital impressions of teeth and gums. Conventional bite ... CAD CAM restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital ...
(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney will be responsible ... the asthma & allergy friendly mark. This certification program was created by ASL and ... products to be more suitable for the 60+ million people living in the U.S. ...
(Date:1/15/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... services. Albertsons Companies is the largest national food and drug chain with ... Accreditation by ACHC reflects Albertsons Companies’ dedication and commitment to meeting national standards ...
(Date:1/15/2017)... ... January 14, 2017 , ... Wondering where to go this Valentine's Day? ... your door for a romantic, lobster feast in the comfort of your own home. ... The dinners will be featured until February 15th, 2017. , Romantic Dinner one ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... Bill is an internationally experienced medical device industry executive who ... global medical device companies, including Smith & Nephew, Angiodynamics, Orthovita and ... and building successful businesses in the sector and has worked in ... North America . ... Educated at the University of Edinburgh (Dental Surgery), ...
(Date:1/16/2017)... Analytics 4 Life (A4L), a machine intelligence company developing ... @ Toronto , one of Johnson ... in the space, A4L has access to a rich ... JLABS @ Toronto ... flexible environment for start-up companies pursuing new technologies and ...
(Date:1/16/2017)... NASHVILLE, Tenn. , Jan. 16, 2017  Cumberland ... addition of Kenneth J. Krogulski , CFA to ... Chief Executive Officer of Berkshire Asset Management LLC ... Berkshire, a 30-year-old independent SEC registered investment advisory firm ... Krogulski has over 37 years, experience in security analysis ...
Breaking Medicine Technology: